|
|
|
|
|
|
|
|
|
|
Abstract
J Cancer Res Ther. 2013 Jan-Mar;9(1):17-21. doi: 10.4103/0973-1482.110343.
Source
Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India.Abstract
Background
and Purpose: Advanced epithelial ovarian cancer is associated with high
relapse rates. Various consolidative therapies, including whole
abdominal radiation therapy (WAR), have been tried in the past with
limited success. We report here a feasibility study and clinical outcome
of WAR with helical tomotherapy (HT).
Materials and Methods: Eight patients with relapsed carcinoma ovary after standard treatment and deemed not suitable for further chemotherapy were treated with WAR using HT. All patients underwent intensity-modulated radiotherapy (IMRT) planning process and a dose of 25Gy/25#, at 1Gy/# to the whole of the abdomen [abdominal planning treatment volume (PTV)] with a simultaneous boost of 45Gy/25#, at 1.8Gy/# to the pelvic PTV was prescribed.
Results: There was an excellent coverage in both abdominal and pelvic PTVs.The V 95% (volume covered by the 95% isodose) and V 107% (volume receiving 107% dose) was 95.6 (±2.7)% and 2.6 (±0.5)% for abdominal PTV and 95.7 (±2.4)% and 0% for pelvic PTV, respectively. With a median follow-up of 15 months (10-24 months, mean: 14 months), 3 patients (out of 8 total patients) developed disease recurrence. All 3 recurred in the peritoneum, one progressed to intestinal obstruction and fatal septicemia.
Conclusion: WAR in recurrent/relapsed epithelial ovarian cancer is feasible with acceptable toxicities.
Materials and Methods: Eight patients with relapsed carcinoma ovary after standard treatment and deemed not suitable for further chemotherapy were treated with WAR using HT. All patients underwent intensity-modulated radiotherapy (IMRT) planning process and a dose of 25Gy/25#, at 1Gy/# to the whole of the abdomen [abdominal planning treatment volume (PTV)] with a simultaneous boost of 45Gy/25#, at 1.8Gy/# to the pelvic PTV was prescribed.
Results: There was an excellent coverage in both abdominal and pelvic PTVs.The V 95% (volume covered by the 95% isodose) and V 107% (volume receiving 107% dose) was 95.6 (±2.7)% and 2.6 (±0.5)% for abdominal PTV and 95.7 (±2.4)% and 0% for pelvic PTV, respectively. With a median follow-up of 15 months (10-24 months, mean: 14 months), 3 patients (out of 8 total patients) developed disease recurrence. All 3 recurred in the peritoneum, one progressed to intestinal obstruction and fatal septicemia.
Conclusion: WAR in recurrent/relapsed epithelial ovarian cancer is feasible with acceptable toxicities.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.